Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Medgenics Reports 2nd Qtr Financial Results.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Subject Terms:
- Abstract:
The article offers information on the second quarter of 2011 financial report of Medgenics Inc. It says that their research and development (R&D) expenses for the three months of the second quarter, which ended on June 30, 2011, was 1.04 million dollars and the six months beginning from January 2011 was 2.22 million dollars, due to the cost of the clinical trials of their Epodure, Infradure, and Hemodure drugs. Furthermore, the net loss for the quarter was 2.32 million dollars.
No Comments.